Antibody Journal
Articles about Antibody Journal (0)
-
Bispecific Antibody Formats – exploring the diverse types & formats in therapeutic development
In this article, we’ll explore the different types and formats of bsAbs, their unique features, and therapeutic applications. Additionally, we’ll highlight evitria’s role in advancing bsAb development.
-
How to choose a bispecific antibody format?
With numerous bispecific formats available, each with its own unique features and advantages, making the right choice can be a complex yet crucial decision. In this article, we will explore the key considerations for choosing a bsAb format.
-
Bispecific antibody development: Effective solutions explored
Developing bispecific antibodies (bsAbs) presents a series of challenges, ranging from optimizing binding affinity and ensuring correct assembly to managing immunogenicity and achieving efficient manufacturing.
-
Advantages of bispecific antibodies
This blog post endeavors to explore the compelling advantages presented by bsAbs and their profound impact on medicine. Additionally, we will highlight the expertise and support provided by evitria in driving forward research and development in this field.
-
What are examples of bispecific drugs?
Bispecific drugs hold immense promise in revolutionizing therapeutic interventions across various medical fields. In this article, we explore three examples of bispecifics and their applications, illuminating their remarkable potential in advancing patient care.
-
What is the difference between a monoclonal and a bispecific antibody?
Both monoclonal and bispecific antibodies come with numerous benefits, but have several differences that set them apart. We will review them in this article.
-
Enhanced purification services for diverse projects
In the dynamic landscape of antibody research and therapeutics, having a diverse array of purification methods is essential. At Evitria AG, we recognize the need for flexibility to meet various project requirements. Let’s delve into our updated purification services.
-
Therapeutic antibodies: afucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC)
Therapeutic antibodies are the fastest-growing class of biological drugs. Their ability to interact with specific targets means they can be employed for a range of diseases, including cancer, autoimmune and infectious diseases.
-
Scalability & Reproducibility – getting it right first time, then again and again…
Delivering material with the same quality at every scale, and with several years in between campaigns, enabled our client to rapidly move through development stages without having to undertake difficult troubleshooting activities or worry about their material quality.
-
Antibody reformatting and engineering – where will your variable domains take you?
The design of your antibody sequence is the single most important step in your therapeutic development journey. Weak binding, off-target effects, and insufficient activity can all improve via sequence engineering.